Navigation Links
Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
Date:5/4/2009

ROCKVILLE, Md., May 4 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will report its 2009 first quarter financial results in a press release to be issued after 8:00 a.m. Eastern Time on Friday, May 8, 2009. The Company will hold an investor conference call to discuss its financial results at 10:00 a.m. Eastern Time on Friday, May 8, 2009. The call will be hosted by Novavax President and Chief Executive Officer Dr. Rahul Singhvi and other members of senior management. A question and answer session will follow the financial results overview. The dial-in number for the conference call is 1 (866) 225 4091 (International: 1 (703) 639 1128.)

A live audio webcast of the conference call will be available at www.novavax.com under Investors/Events. Please connect to this website at east 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. A replay of the webcast will be available on the website for 90 days after the call and a replay of the conference call will also be available by telephone beginning May 8, 2009 at 1:00 p.m. through May 13, 2009 at 11:59 p.m. To access the replay, dial 1 (888) 266 2081 and enter pass code 1357908.

About Novavax, Inc.

Novavax, Inc. is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. Additional information about Novavax is available at www.novavax.com and in the Company's various filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Novavax Announces Early Retirement of $17 Million of Convertible Debt
2. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
3. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
4. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
5. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
6. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
7. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
8. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
9. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
10. Novavax CMO to Present at Phacilitate Vaccine Forum Washington 2009
11. NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... Clara, CA (PRWEB) , ... February 22, 2017 , ... ... hosting a free AFM Luncheon for all SPIE attendees and ... Jose, CA, just one block from the San Jose Convention Center. The luncheon ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... the leading medical education provider of women’s health, primary care, and specialty ... Council for Continuing Medical Education (ACCME). ACCME’s Accreditation with Commendation is a ...
(Date:2/22/2017)... Yorba Linda, Ca (PRWEB) , ... February 22, 2017 , ... ... tech innovators, engineers, and scientists from around the world, is pleased to announce the ... the science, technology, engineering and mathematics (STEM) fields. , This merit-based scholarship is open ...
(Date:2/22/2017)... -- Aethlon Medical, Inc. (Nasdaq: AEMD ), ... the ability of the Aethlon Hemopurifier® to capture latent ... immune-suppressed sepsis patients and also contribute to organ rejection ... the study was to validate the in vitro ... Herpes Simplex virus 1 (HSV1) by the Hemopurifier®. The ...
Breaking Biology Technology:
(Date:2/8/2017)... -- Report Highlights The global biosurgery market ... in 2016 at a compound annual growth rate (CAGR) ... - An overview of the global market for biosurgery. ... 2015 and 2016, and projections of compound annual growth ... on the basis of product type, source, application, and ...
(Date:2/7/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... the LEERINK Partners 6th Annual Global Healthcare Conference at ... 15, 2017 at 10 a.m. Eastern Time. ... accessed at http://wsw.com/webcast/leerink28/zbh .  The webcast will be ... Investor Relations website at http://investor.zimmerbiomet.com . ...
(Date:2/6/2017)... 2017 According to Acuity Market Intelligence, ... authorities to continue to embrace biometric and digital ... Automated Border Control (ABC) eGates and 1436 Automated ... than 163 ports of entry across the globe. ... a combined CAGR of 37%. APC Kiosks reached ...
Breaking Biology News(10 mins):